gastro-congress-2016_posters-accepted-abstracts

19 / 22

Volume 6, Issue 7(Suppl) J Gastrointest Dig Syst 2016
ISSN: 2161-069X JGDS, an open access journal
Page 69
Gastro Congress 2016
October 24-25, 2016
conferenceseries.com
October 24-25, 2016 Valencia, Spain
9th Euro Global
Gastroenterology Conference
J Gastrointest Dig Syst 2016, 6:7(Suppl)
Endometriotic cyst mimicking a retroperitoneal tumor – A rare scenario
K B Sriraman
Sri Ramachandra University, India
Ectopic endometrial tissues are rarely observed on the serosal surfaces of bowel and laparotomy incisions, in the lungs,
bones and in the urinary tract. A few case reports of endometriosis in the retroperitoneal location has been reported in the
English literature. Endometriotic cyst in a retroperitoneal location mimicking a retroperitoneal tumor through the mesentery
of sigmoid colon is an extremely rare presentation. A 45 year old woman presented with pain abdomen of 3 months duration.
CT abdomen & pelvis revealed a retroperitoneal mass adjacent to left psoas and left ureter. On laporotomy, a cystic mass was
found in the retroperitoneum over the left common iliac vessels. The mass was excised in to preserving the left ureter, left
iliac vessels and sigmoid colon. The final histopathology revealed an endometriotic cyst. Recto-sigmoid junction is the most
common site of extra-genital endometriosis, with less frequent sites being the rectovaginal septum, small intestine, cecum and
appendix. Retroperitoneal presentation of endometriotic cyst is a rare presentation and only few cases have been reported.
Retroperitoneal endometriotic cyst may mimic a retroperitoneal tumor in view of the location. Retroperitoneal endometriotic
cyst in the sigmoid mesentery is an extremely rare presentation. Whenever a CT guided biopsy was not diagnostic in a
retroperitoneal lesion, complete excision is the treatment of choice to arrive at a final diagnosis.
Assessment of the therapeutic effect of allopurinol on patients with non-alcoholic fatty liver
disease associated with hyperuricemia by cytokeratin 18
Sylvia S Sedhom1, Osama A Badary2, Salwa H Salama1 and Mohamad A Mokhles1
1National Research Center, Egypt
2Ain Shams University, Egypt
Background: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver injury. Elevated uric
acid (UA) is an important factor in the development of NAFLD. Both combined result in apoptosis which is an important
mechanism in pathogenesis of NAFLD, where it leads to activation of caspase family of intracellular proteases which then
cleave different intracellular proteins including cytokeratin 18 (CK18) which can be used as a key marker in NAFLD.
Objective: The objective of this study is to evaluate the effect of treating hyperuricemia by allopurinol on NAFLD patients by
blood markers as CK18, liver enzymes (GOT, GPT), cholesterol (Chol) and triglyceride (TG).
Methods: In this study, 31 hyperuricemic patients with NAFLD diagnosed by ultrasound were enrolled in the study and
divided into two groups; Group A (14 patients): Placebo group who received starch based tablets for 3 months and Group B
(17 patients): Treatment group who received allopurinol (300 mg) for 3 months. UA, CK 18, GPT, GOT, Chol and TG were
measured before and after treatment.
Results: The study showed a significant decline in CK18 levels after treatment (P=0.006), improvement in GPT and GOT levels
after treatment (P<0.001 and P=0.013, respectively), also there was an improvement in Chol and TG levels after treatment
(P=0.01 and 0.038, respectively).
Conclusion: Allopurinol may play a role in improvement of patients with NAFLD associated with hyperuricemia and CK18
may be used as a good marker in assessing patients’ improvement.